Atrial fibrillation (AF) is the most commonly sustained disorder of cardiac rhythm, and increases the risk for stroke. 1 Hypertension is a common comorbidity in AF patients, and it has been found to be an independent risk factor for stroke in those patients. Hypertension is included in the stroke risk prediction schemes in AF patients, such as the CHADS 2 score 2 and the CHA 2 DS 2 -VASc score. 3 Previous studies have found an elevated risk of stroke in AF patients who have a history of hypertension regardless of blood pressure (BP) control, 4-6 whereas other studies found an elevated risk of stroke according to systolic BP (SBP) level. 7-12 Thus, controversy exists regarding whether a history of hypertension or BP control level is more associated with the risk of stroke in AF patients. Moreover, the association of hypertension and BP control with the type of stroke (ischemic or hemorrhagic) is less understood. Hypertension is also closely associated with bleeding risk in patients with AF, especially in those receiving anticoagulant therapy, 9, 11, 13 and it is included in the HAS-BLED score, a simple and practical tool to assess the bleeding risk of such patients, in which "H" refers to uncontrolled hypertension (SBP > 160 mm Hg), not simply history of hypertension. 14 A subanalysis of the J-RHYTHM registry recently reported that BP control is more important than a history of hypertension in the prevention of thromboembolism as well as major bleeding in Japanese patients with AF. 15 The purpose of this study was to investigate the relationship of hypertension and SBP with the risk of stroke/systemic embolism (SE) or bleeding in Japanese AF patients using data from the Fushimi AF Registry. 
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Atrial fibrillation (AF) is the most commonly sustained disorder of cardiac rhythm, and increases the risk for stroke. 1 Hypertension is a common comorbidity in AF patients, and it has been found to be an independent risk factor for stroke in those patients. Hypertension is included in the stroke risk prediction schemes in AF patients, such as the CHADS 2 score 2 and the CHA 2 DS 2 -VASc score. 3 Previous studies have found an elevated risk of stroke in AF patients who have a history of hypertension regardless of blood pressure (BP) control, [4] [5] [6] whereas other studies found an elevated risk of stroke according to systolic BP (SBP) level. [7] [8] [9] [10] [11] [12] Thus, controversy exists regarding whether a history of hypertension or BP control level is more associated with the risk of stroke in AF patients. Moreover, the association of hypertension and BP control with the type of stroke (ischemic or hemorrhagic) is less understood. Hypertension is also closely associated with bleeding risk in patients with AF, especially in those receiving anticoagulant therapy, 9, 11, 13 and it is included in the HAS-BLED score, a simple and practical tool to assess the bleeding risk of such patients, in which "H" refers to uncontrolled hypertension (SBP > 160 mm Hg), not simply history of hypertension. 14 A subanalysis of the J-RHYTHM registry recently reported that BP control is more important than a history of hypertension in the prevention of thromboembolism as well as major bleeding in Japanese patients with AF. 15 The purpose of this study was to investigate the relationship of hypertension and SBP with the risk of stroke/systemic embolism (SE) or bleeding in Japanese AF patients using data from the Fushimi AF Registry.
METHODS
The Fushimi AF Registry is a community-based prospective survey of AF patients in Fushimi-ku, Kyoto, Japan. [16] [17] [18] [19] The detailed study design, patient enrollment, participating institutions, definition of the comorbidities or measurements, and patient baseline clinical characteristics of the Fushimi AF Registry were previously described (UMIN Clinical Trials Registry: UMIN000005834). 16 The inclusion criterion for the registry is the documentation of AF on a 12-lead electrocardiogram or Holter monitoring at any time. There are no exclusion criteria for this "all-comers" registry. A total of 80 institutions, all of which are members of Fushimi-Ishikai (Fushimi Medical Association), participated in the registry. The participating institutions comprised 2 cardiovascular centers (National Hospital Organization Kyoto Medical Center and Ijinkai Takeda Hospital), 10 small-and mediumsized hospitals, and 68 primary care clinics. The enrollment of patients was started in March 2011. All of the participating institutions attempted to enroll all consecutive patients with AF under regular outpatient care or hospital admission.
Clinical data of the patients were registered in an internet database (https://edmsweb16.eps.co.jp/edmsweb/002001/ FAF/top.html, last accessed at 22 May 2017) by the doctors in charge at each institution. Data were automatically checked for missing or contradictory entries and values out of the normal range. Additional editing checks were performed by clinical research coordinators at the general office of the registry. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki, and was approved by the ethics committees of the National Hospital Organization Kyoto Medical Center and Ijinkai Takeda General Hospital.
We defined the primary endpoint as composite endpoint of "stroke/SE" during the follow-up period. Stroke was defined as the sudden onset of a focal neurologic deficit in a location consistent with the territory of a major cerebral artery, and it was confirmed by computed tomography or magnetic resonance imaging. SE was defined as an acute vascular occlusion of an extremity or organ. Oral anticoagulants (OAC) included warfarin, dabigatran, rivaroxaban, apixaban, and edoxaban. Antiplatelet therapy was defined as the use of aspirin, thienopyridine, or cilostazol. Hypertension was diagnosed if peripheral BP was >140/90 mm Hg or if the patient was taking medication for hypertension. In this analysis, we divided hypertension patients by baseline SBP (HTN-low blood pressure [LBP] group as baseline SBP <150 mm Hg, HTN-high blood pressure [HBP] group as baseline SBP ≥150 mm Hg). Office BP was measured once at study entry and any point during the follow-up.
Major bleeding was defined as a reduction in the hemoglobin level of at least 2 g/dl, transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ. All other bleeding was considered minor.
The CHADS 2 scoring adds together the points that correspond to the following conditions: congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, prior stroke, or transient ischemic attack (2 points). 2 The CHA 2 DS 2 -VASc scoring is a refinement of the CHADS 2 score and extends it by including additional common stroke risk factors: age (patients ≥75 years old receive 2 points and patients 65-74 years old receive 1 point), vascular disease, and female gender. 3 The HAS-BLED score is an acronym for hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio (INR), elderly (≥65), and drugs/alcohol concomitantly. 14 "L" was not assessed because labile INR data were unavailable in the present study and drugs of "D" was replaced by the concomitant use of antiplatelet drugs.
Statistical analysis
Continuous variables are expressed as mean ± SD. Categorical variables are presented as numbers and percentages. We compared categorical variables using the chi-square test when appropriate; otherwise, we used Fisher's exact test. We compared continuous variables using Student's t-test on the basis of the distribution. Data were analyzed as crude and stratified by history of hypertension and SBP, which were collected at the time of entry into the study. KaplanMeier analysis was used to estimate event-free survival, and the log-rank test was used to compare survival across the groups. Cox proportional hazards regression model was used to calculate the hazard ratio (HR) of some predictive factors and their 95% confidence interval (CI) for the incidence of clinical events. We used JMP version 12 (SAS Institute, Cary, NC) to perform all of these analyses. Two-sided P-values less than 0.05 were considered statistically significant.
RESULTS

Baseline characteristics
A total of 4,392 patients were enrolled in the Fushimi AF Registry by August 2015. Of 4,124 patients who were enrolled 1 year before, follow-up data (collected every year) were available for 3,713 patients (follow-up rate: 90.0%). We compared the clinical backgrounds at baseline between patients with hypertension (HTN; n = 2,304, 62% of total) and those without (non-HTN; n = 1,409, 38%) ( Table 1 ). The mean BP at baseline was 128.2 ± 19.1/71.5 ± 12.9 mm Hg for the HTN group and 119.0 ± 17.6/69.0 ± 12.5 mm Hg for the non-HTN group, respectively. The HTN group was older (HTN vs. non-HTN: 74.4 vs. 72.4 years; P < 0.01), had more comorbidities (such as diabetes mellitus, dyslipidemia, chronic kidney disease, and vascular disease), and thus had a higher CHADS 2 score (HTN vs. non-HTN: 2.49 vs. 1.27; P < 0.01) and CHA 2 DS 2 -VASc score (3.88 vs. 2.53; P < 0.01). The HAS-BLED score was also greater in the HTN group (HTN vs. non-HTN: 1.70 vs. 1.42; P < 0.01).
The HTN group received β-blockers, rennin-angiotensin system inhibitors and calcium channel blockers more frequently than the non-HTN group (β-blockers; HTN vs. non-HTN: 31.1% vs. 25.1%, rennin-angiotensin system inhibitors; 61.8% vs. 15.6%, calcium channel blockers; 46.0% vs. 6.6%). These drugs may have been given for rate control or the treatment of coexisting heart failure in the non-HTN group. The HTN group received OAC prescriptions more frequently than the non-HTN group (55.1% vs. 50.6%; P < 0.01), but the percentage of patients with previous stroke/SE was comparable (21.5% vs. 19.0%; P = 0.07).
Outcomes
Kaplan-Meier curves for the incidence of major clinical events in HTN and non-HTN groups are shown in Figure 1 . A history of hypertension was neither associated with the incidence of stroke/SE, ischemic stroke, hemorrhagic stroke nor major bleeding.
The crude incidences of major clinical events in HTN and non-HTN groups during the follow-up period including death and myocardial infarction as well as stroke/SE and bleeding are shown in Table 2 . The incidences of ischemic stroke and major bleeding were higher in HTN group than non-HTN group, but all of them were statistically comparable between HTN and non-HTN groups.
With respect to the outcome of stroke/SE, statistical tests for interaction were not significant in any of the major subgroups stratified by gender, age, type of AF, major comorbidities, or the use of OAC (Figure 2 ). Data are presented as n (%) or mean ± SD. Vascular disease: myocardial infarction or peripheral arterial disease. Abbreviations: AF, atrial fibrillation; CCB, calcium channel blocker; HBP, high blood pressure; HTN, hypertension; LBP, low blood pressure; RASI, rennin-angiotensin system inhibitor; SE, systemic embolism. Table 3 showed the incidences of stroke/SE and major bleeding in the HTN groups divided by baseline SBP at every 10 mm Hg and the non-HTN group. Patients with SBP ≥150 mm Hg at baseline was significantly correlated with a higher incidence of stroke/SE and major bleeding compared with the non-HTN group (stroke/SE; HR: 1.74, 95% CI: 1.08-2.72, P = 0.023, major bleeding; HR: 2.01, 95% CI:
1.21-3.23, P = 0.008). In addition, all the subgroups of the HTN group with SBP <150 mm Hg (−119, 120-129, 130-139, 140-149) were at comparable risk with the non-HTN group. Therefore, we divided the HTN group into 2 groups; HTN-HBP with SBP ≥150 mm Hg (n = 305, 13.3% of HTN group), and HTN-LBP with SBP <150 mm Hg (n = 1,983, 86.7%). Similarly, Table 4 showed the incidences of stroke/ SE and major bleeding in the HTN groups divided by baseline pulse pressure at every quartile. Patients with the highest pulse pressure level at baseline was significantly correlated with a higher incidence of stroke/SE and major bleeding compared with the non-HTN group (stroke/SE; HR: 1.52, 95% CI: 1.02-2.24, P = 0.041, major bleeding; HR: 1.71, 95% CI: 1.11-2.60, P = 0.015). The impact of both SBP and pulse pressure on the risk of stroke/SE and major bleeding was more clearly observed in OAC users rather than OAC nonusers.
Comparison of baseline characteristics between HTN-HBP and HTN-LBP is shown in Table 1 . The HTN-HBP group had more females and less history of heart failure than the HTN-LBP group, but age and major comorbidities were similar between the 2 groups. The CHADS 2 score (HTN-HBP vs. HTN-LBP: 2.50 vs. 2.49; P = 0.89) and CHA 2 DS 2 _VASc score (HTN-HBP vs. HTN-LBP: 3.92 vs. 3.88; P = 0.64) were also similar between the 2 groups. The HAS-BLED score was greater in the HTN-HBP group (HTN-HBP vs. HTN-LBP: 2.08 vs. 1.65; P < 0.01). Kaplan-Meier curves for the incidence of stroke/SE, ischemic stroke, hemorrhagic stroke, and major bleeding in HTN-HBP, HTN-LBP, and non-HTN groups are shown in Figure 3 . The incidences of stroke/SE, hemorrhagic stroke, and major bleeding were significantly different among the 3 groups (log rank P = 0.049 for stroke/SE, 0.045 for hemorrhagic stroke, 0.009 for major bleeding), whereas that of ischemic stroke was not (log rank P = 0.23). HTN-HBP group was significantly associated with a higher incidence of both stroke/SE (HR: 1.74, 95% CI: 1.08-2.72) and major bleeding (HR: 2.01, 95% CI: 1.21-3.23) compared with the non-HTN group, but the difference did not reach statistical significance when stroke was divided by type, ischemic stroke (HR: 1.53, 95% CI: 0.83-2.68) and hemorrhagic stroke (HR: 1.95, 95% CI: 0.85-4.10). In contrast, HTN-LBP was not associated with the risk of stroke/SE (HR: 1.11, 95% CI: 0.82-1.50) or major bleeding (HR: 1.06, 95% CI: 0.75-1.49), compared with the non-HTN group. HR of some events such as stroke/ SE, ischemic stroke, hemorrhagic stroke, and major bleeding compared by average SBP which was measured at entry and follow-up are shown in Supplementary Table 1. Mean times of SBP measurement were 3.12 during the follow-up. The higher average BP in HTN group (average SBP ≥150 mm Hg) was significantly associated with a higher incidence of both hemorrhagic stroke and major bleeding compared with both the lower average BP in HTN group (average SBP < 150 mm Hg) and the non-HTN group. Relative risk of the primary outcome of stroke/SE, according to major prespecified subgroups. Data are presented as incidence rate (total events) per 100 person-years. Abbreviations: AF, atrial fibrillation; CCB, calcium channel blocker; CI, confidence interval; RASI, rennin-angiotensin system inhibitor; SE, systemic embolism. Each HTN group was compared with the non-HTN group. Data are presented as incidence rate per 100 person-years. Abbreviations: CI, confidence interval; HR, hazard ratio; HTN, hypertension; OAC, oral anticoagulants; SBP, systolic blood pressure; SE, systemic embolism. 
DISCUSSION
This is one of the largest community-based prospective cohorts of Asian subjects with AF, in which we examined the association between history of hypertension and SBP level with the risk of stroke/SE or bleeding in patients with AF. We found that the incidences of stroke/SE and bleeding were equivalent between patients with and without a previous history of hypertension, but were higher in patients with hypertension with high baseline SBP level. In addition, wellcontrolled hypertension was not associated with the risk of stroke or major bleeding.
Hypertension and stroke/SE in AF patients
Hypertension is a strong, consistent, independent risk factor for stroke in patients with AF. 2, 5, 6, 20 Hypertension is the most common comorbid condition in patients with AF and/or AF-associated stroke. 5 However, it remains unclear whether well-treated hypertension is a risk for stroke, and whether SBP level is associated with the risk of stroke in AF patients. The Copenhagen AFASAK study demonstrated that diagnosed hypertension was associated with the risk of stroke/SE regardless of BP control. 6 In addition, the Stroke Prevention in Atrial Fibrillation (SPAF) trial demonstrated that SBP ≥160 mm Hg was independently associated with increased risk of stroke/SE. 12 In the ACTIVE-W trial, AF patients with a baseline SBP above the median value experienced a much higher risk of stroke, whereas patients with a baseline SBP below the median value had a low rate of stroke. 21 In the subanalysis of the RE-LY trial comparing dabigatran and warfarin in AF patients, there was a 6-7% increased risk of stroke for every 10 mm Hg increase in mean BP (P = 0.046) and SBP (P = 0.016). 11 Similarly, the subanalysis of the ARISTOTLE trial comparing apixaban and warfarin showed that HBP at any point during the study period was associated with higher risk of stroke/SE. 9 Our present results showed that a history of hypertension was not associated with the risk of stroke/SE in AF patients (Figure 1a) . Poorly controlled hypertension (defined as SBP ≥150 mm Hg in this analysis) was associated with increased risk of stroke/SE (Figure 3a ), but such patients accounted for only 13% of the HTN group, which suggests that hypertension was generally well-controlled in contemporary clinical practice. Mean SBP in the HTN group was 128 mm Hg in the Fushimi AF Registry, which was much lower than previous studies conducted in the 1990s, from which the CHADS 2 score was derived. 2, 12, 22 The HTN-LBP group demonstrated equivalent stroke risk compared with the non-HTN group, clearly indicating the critical importance of BP control to lower the risk of stroke in AF patients. In good agreement with our results, Kodani et al. recently revealed that BP control rather than the history of hypertension was associated with the elevated risk of thromboembolism from the subanalysis of the J-RHYTHM registry. 15 
Hypertension and ischemic/hemorrhagic stroke in AF patients
The association of hypertension and SBP level with the type of stroke (ischemic or hemorrhagic) is less understood. In the ARISTOTLE subanalysis, both history of hypertension and elevated SBP at baseline (≥140 mm Hg) were associated with the risk of stroke/SE (adjusted HR: 1.33 for a history of hypertension and 1.24 for elevated SBP), but the association was not significant when stroke type was divided into ischemic and hemorrhagic. 9 In the present study, the HTN-HBP group showed a significantly greater risk of stroke/ SE than the non-HTN (HR: 1.74, 95% CI: 1.08-2.72), and a similar trend appeared present for both ischemic stroke (HR: 1.53, 95% CI: 0.83-2.68) and hemorrhagic stroke (HR: 1.95, 95% CI: 0.85-4.10), but the difference did not reach statistical significance, perhaps due to the insufficient number of patients/events in the HTN-HBP group (Figure 3a-c) .
Hypertension and bleeding in AF patients
Hypertension (diagnosed hypertension or elevated BP) is included in the currently used bleeding risk scores. High SBP (≥160 mm Hg), but not well-controlled hypertension, is included in the HAS-BLED score. 8, 14, 23 In the ATRIA bleeding risk score, diagnosed hypertension is regarded as 1 of the 5 most predictive risk factors, irrespective of the SBP level. 24 In the RE-LY subanalysis, patients with diagnosed hypertension had a greater risk of major bleeding (HR: 1.25, 95% CI: 1.06-1.46), but a similar risk of intracranial bleeding (HR: 1.46, 95% CI: 0.91-2.36) compared with patients without hypertension. 11 In the J-RHYTHM registry subanalysis, both the risks of major bleeding and intracranial hemorrhage were significantly higher in patients with SBP ≥136 mm Hg, again underlining the importance of BP control. 15 In the present study, a history of hypertension was not associated with any of the adverse events including major bleeding (Figure 1d ), but HTN-HBP (SBP ≥150 mm Hg) resulted in higher incidences of major bleeding (Figure 3d ).
LIMITATIONS
First, the results come from an observational study and provide only associative evidence, not causative. Second, we divided HTN patients into HBP and LBP groups by use of a single baseline SBP level, which may fluctuate due to SBP variability. Third, our analysis used 150 mm Hg as a cutoff based on the stratification of SBP (Table 3 ), but we do not suggest 150 mm Hg as a target value in BP control given the limited number of patients in this study using single baseline SBP. Fourth, there is the lack of data on changes in antihypertensive therapies at follow-up and we also have no data on time in therapeutic range for individual patients taking warfarin. Fifth, this cohort consists of Japanese population, so the study results may not be applicable to other Asian (or non-Asian) populations.
CONCLUSION
The incidences of stroke/SE and bleeding were higher in AF and hypertension patients with elevated SBP.
SUPPLEMENTARY MATERIAL
Supplementary data are available at American Journal of Hypertension online.
